Nature Communications (Aug 2021)
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
- Fabian Frontzek,
- Annette M. Staiger,
- Myroslav Zapukhlyak,
- Wendan Xu,
- Irina Bonzheim,
- Vanessa Borgmann,
- Philip Sander,
- Maria Joao Baptista,
- Jan-Niklas Heming,
- Philipp Berning,
- Ramona Wullenkord,
- Tabea Erdmann,
- Mathias Lutz,
- Pia Veratti,
- Sophia Ehrenfeld,
- Kirsty Wienand,
- Heike Horn,
- John R. Goodlad,
- Matthew R. Wilson,
- Ioannis Anagnostopoulos,
- Mario Lamping,
- Eva Gonzalez-Barca,
- Fina Climent,
- Antonio Salar,
- Josep Castellvi,
- Pau Abrisqueta,
- Javier Menarguez,
- Teresa Aldamiz,
- Julia Richter,
- Wolfram Klapper,
- Alexandar Tzankov,
- Stefan Dirnhofer,
- Andreas Rosenwald,
- José Luis Mate,
- Gustavo Tapia,
- Peter Lenz,
- Cornelius Miething,
- Wolfgang Hartmann,
- Björn Chapuy,
- Falko Fend,
- German Ott,
- José-Tomas Navarro,
- Michael Grau,
- Georg Lenz
Affiliations
- Fabian Frontzek
- Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster
- Annette M. Staiger
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen
- Myroslav Zapukhlyak
- Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster
- Wendan Xu
- Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster
- Irina Bonzheim
- Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen-Comprehensive Cancer Center, University Hospital Tübingen
- Vanessa Borgmann
- Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen-Comprehensive Cancer Center, University Hospital Tübingen
- Philip Sander
- Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen-Comprehensive Cancer Center, University Hospital Tübingen
- Maria Joao Baptista
- Department of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona
- Jan-Niklas Heming
- Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster
- Philipp Berning
- Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster
- Ramona Wullenkord
- Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster
- Tabea Erdmann
- Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster
- Mathias Lutz
- Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster
- Pia Veratti
- Department of Psychiatry and Psychotherapy, University Hospital Freiburg
- Sophia Ehrenfeld
- Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg
- Kirsty Wienand
- Department of Hematology and Medical Oncology, University Medical Center Göttingen
- Heike Horn
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen
- John R. Goodlad
- Department of Pathology, Queen Elizabeth University Hospital
- Matthew R. Wilson
- Department of Haematology, Beatson West of Scotland Cancer Centre
- Ioannis Anagnostopoulos
- Institute of Pathology, University of Würzburg
- Mario Lamping
- Charité Comprehensive Cancer Center, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health
- Eva Gonzalez-Barca
- Department of Hematology. ICO-Hospital Duran i Reynals, Universitat de Barcelona, L’Hospitalet de Llobregat
- Fina Climent
- Department of Pathology. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat
- Antonio Salar
- Department of Hematology, Hospital del Mar
- Josep Castellvi
- Department of Pathology, Hospital Universitari Vall d’Hebron
- Pau Abrisqueta
- Department of Hematology, Hospital Universitari Vall d’Hebron
- Javier Menarguez
- Department of Pathology, Hospital Gregorio Marañón
- Teresa Aldamiz
- Department of Infectious Diseases, Hospital Gregorio Marañón
- Julia Richter
- Division of Hematophathology, Christian-Albrechts-University
- Wolfram Klapper
- Division of Hematophathology, Christian-Albrechts-University
- Alexandar Tzankov
- Institute of Medical Genetics and Pathology, University Hospital Basel
- Stefan Dirnhofer
- Institute of Medical Genetics and Pathology, University Hospital Basel
- Andreas Rosenwald
- Institute of Pathology, University of Würzburg
- José Luis Mate
- Department of Pathology, Hospital Germans Trias i Pujol, Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona
- Gustavo Tapia
- Department of Pathology, Hospital Germans Trias i Pujol, Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona
- Peter Lenz
- Department of Physics, University of Marburg
- Cornelius Miething
- Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg
- Wolfgang Hartmann
- Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster
- Björn Chapuy
- Department of Hematology and Medical Oncology, University Medical Center Göttingen
- Falko Fend
- Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen-Comprehensive Cancer Center, University Hospital Tübingen
- German Ott
- Department of Clinical Pathology, Robert Bosch Hospital
- José-Tomas Navarro
- Department of Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona
- Michael Grau
- Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster
- Georg Lenz
- Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster
- DOI
- https://doi.org/10.1038/s41467-021-25405-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Plasmablastic lymphoma (PBL) is an aggressive lymphoma subtype characterized by poor prognosis but the molecular knowledge of the disease is limited. Here, the authors perform whole exome sequencing and copy number determination of primary samples highlighting IRF4 and JAK-STAT pathways as therapeutic targets for PBL.
